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Summary: A simple method for the determination of the three isozymes of alkaline phosphatase (EC 3.1.3.1)
! contained in amniotic fluid (fetal intestinal, placental, and liver-bone-kidney) is presented. Total alkaline phospha-
tase activity was assayed in 10 000 g supernatants of amniotic fluid from 30 normal women between the 16th and
20th week of pregnancy. Electrophoretic patterns and inhibition by L-phenylalanine and L-homoarginine studies
showed that all the fetal intestinal isozyme was precipitated in the pellet after centrifugation at 100 000 g for 90 min.
Thus, the difference between total alkaline phosphatase activity and activity in the 100 000 g supernatant corre-
sponds to fetal intestinal alkaline phosphatase. Placental isozyme can be determined by assaying alkaline phospha-
tase in the 100 000 g supernatant after heating at 56 °C for 90 min. Liver-bone-kidney isozyme activity is obtained
by subtracting placental alkaline phosphatase activity from that of the 100 000 g supernatant. Mean percentages of
the total alkaline phosphatase for each of the isozymes in amniotic fluid were 81% for fetal intestinal alkaline
phosphatase, 7.5% for placental alkaline phosphatase and 12.0% for liver-bone-kidney alkaline phosphatase.
Determination of fetal intestinal alkaline phosphatase by this method could be applied to the diagnosis of cystic
fibrosis in fetuses having a 1 : 4 risk of being affected.
Introduction
Human alkaline phosphatase (EC 3.1.3.1)1) exists as
three isozymes with different tissue distribution: intesti-
nal, placental and liver-bone-kidney. The three molecu-
lar forms can be identified on the basis of electropho-
retic mobility, sensitivity to inhibitors, immunochemis-
try and heat stability (1). During the second trimester of
pregnancy, amniotic fluid contains the three isozymes,
although the intestinal form shows some differences to
that found in adult intestinal microvilli. The fraction iso-
lated from amniotic fluid is designated fetal intestinal
alkaline phosphatase. The enzyme is located in the fetal
small intestine mucosa. Since the microvilli are continu-
ously desquamating into the lumen, their membranes
and debris are incorporated into the meconium and nor-
mally pass to the amniotic fluid, especially during the
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second trimester of gestation (1). Fetuses affected by
cystic fibrosis have a thickened meconium which slows
down intestinal transit. Thus, less meconium is liberated
to the amniotic fluid and the amount of fetal intestinal
alkaline phosphatase in this fluid is substantially re-
duced (2, 3). Determination of activity in amniotic fluid
between the 15th and 20th week of pregnancy has been
proposed as a sensitive method for prenatal diagnosis of
cystic fibrosis (4, 5). Thanks to the advances of molecu-
lar biology, other valuable diagnostic methods are avail-
able. Studies of restriction fragment length polymor-
phism of DNA segments of chromosome 7 indicated the
existence of some "marker" restriction fragments linked
to cystic fibrosis. Later isolation of the cystic fibrosis
gene allowed a panel of probes to be obtained recogniz-
ing the most common mutations causing the disease.
These techniques allow accurate diagnosis in a high per-
centage of cases (6—8). However, even admitting the
possibility of false positive and negative results (about
3% and 8%, respectively) (4), enzyme determination in
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amniotic fluid is still a reliable method. It is approxi-
mately 90% accurate in cases of couples with cystic fi-
brosis and a 1 : 4 risk of having another cystic fibrosis
baby (5). Presently available methods for fetal intestinal
alkaline phosphatase determination involve use of mo-
noclonal antibodies, availability of purified control iso-
zymes or utilization of combined inhibitors, which com-
plicate the procedure and are not simple enough for
general use in the clinical laboratory (9, 10). We present
here a method for the determination of isozymes of alka-
line phosphatase in amniotic fluid and a simple tech-
nique for separation of fetal intestinal alkaline phospha-
tase.
Materials and Methods
Amniot ic f luid
Thirty samples of amniotic fluid were obtained by amniocentesis
of normal women being monitored for chromosomal abnormalities
between the 16th and 20th week of pregnancy. The fluid was
centrifuged at 1000 g for 10 min to separate suspended cells. The
supernatant was centrifuged at 10 000 g for 15 min to precipitate
remaining debris. A 4 ml aliquot of the supernatant was then centri-
fuged at 100 000 g for 90 min. The pellet was suspended in 0.2 ml
of 50 mmol/1 Tris-HCl buffer, pH 7.0 and used for enzyme assays
and electrophoretic studies. A 2.0 ml aliquot of the supernatant was
incubated in a water-bath at 56 °C for 90 min and then cooled
on ice.
Intest inal tissue
Duodenum and jejunum were obtained within 24 h post-mortem at
autopsy of adult human free of intestinal pathology. Mucosa was
scrapped with a razor blade and stored at —23 °C.
Meconium
It was obtained immediately after birth of normal babies and stored
at -23 °C until used for enzyme extraction.
Extraction of a lkal ine phosphatase
Fetal and adult intestinal alkaline phosphatase were extracted from
meconium and adult mucosa, respectively by butanolic treatment
following the technique described by Morton (11).
Enzyme assay
Alkaline phosphatase (EC 3.1.3.1) assay was performed at 37 °C
in 2 ml of a reagent mixture containing 3 mmol/1 p-nitrophenyl-
phosphate, 0.5 mmol/1 MgCl2, 0.5 mmol/1 diethanolamine pH 9.8
and 0.3 ml of the 10 000 g supernatant of amniotic fluid. Reaction
was stopped after 30 min by addition of 3 drops of 400 g/1 NaOH.
Absorbance was read at 405 nm. All determinations were carried
out by duplicate and the activity expressed in Units per 1 of sample.
One Unit is the amount of enzyme catalyzing the conversion of
1 μηιοί of substrate per min in the assay conditions (12).
Electrophoresis
It was performed in 6.5% polyacrylamide gel with the micro-
method described by Ogita & Marken (13) after addition of 1 g/1
Triton X-100 to the preparation. The samples were run with 12.5
mmol/1 Tris-glycine pH 8.3 during 90 min at 200 V and 20 mA
per gel. After electrophoresis was performed, alkaline phosphatase
isozymes were revealed by staining with a mixture containing:
58 ml 100 mmol/I Tris/HCl pH 9.0, 2 ml MgCl2 50 mmoi/i, 50 mg
a-naphthyl acid phosphate monosodium salt and 25 mg Fast Blue
RR salt. The mixture was filtered and used immediately, staining
was performed in the dark (14).
Results
Characterization of the alkaline phosphatase
isozymes in amniotic fluid
The 100 000 g pellet suspended in 50 mmol/1 Tris-HCl
buffer pH 7.0 was submitted to electrophoresis after ad-
dition of Triton X-100. Specific staining for alkaline
phosphatase revealed a zone of intense activity (fig. 1A).
Without Triton X-100, all the alkaline phosphatase activ-
ity in the pellet is retained at the origin (fig. IF). Pellet
extracts with butan l at pH 5.0, run under same condi-
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Fig. l Alkaline phosphatase electrophoretic patterns in polyacryl-
amide gels.
A - Suspension of amniotic fluid 100 000 g pellet treated with
Triton X-100.
B - Butanolic extract at pH 5 from suspension of amniotic fluid
100 000 g pellet.
C - Butanolic extract at pH 5 from suspension of amniotic fluid
100 000 g pellet treated with neuraminidase.
D — Butanolic extract at pH 5 from meconium treated with neur-
aminidase.
E - Butanolic extract at pH 5 from meconium.
F - Suspension of 100 000 g pellet from amniotic fluid without
Triton X^ 100.
G - Butanolic extract at pH 5 from adult intestinal tissue.
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tions, showed a region of staining with a mobility about
twice as fast as that of the original preparation treated
with Triton X-100 (fig. IB). When the pellet butanolic
extract was previously incubated with neuroaminidase
0.2 kU/1 at 37 °C for 2 h the mobility of the band was
slightly reduced (fig. 1C). Alkaline phosphatase ex-
tracted from meconium by butanol at pH 5.0 treated and
non-treated with neuraminidase presented the same
velocity of migration as the band observed in the pellet
preparations processed under the same conditions (fig.
ID and IE). The enzyme extracted from adult intestinal
mucosa gave a band with the same mobility as those in
the amniotic fluid pellet and meconium after incubation
with neuraminidase (fig. IG). Electrophoretic studies of
the amniotic fluid 100 000 g supernatant concentrated 20
times by ultrafiltration and incubated with neuramini-
dase to stress differences in mobility between the fetal
intestinal alkaline phosphatase and the other isozymes
present in amniotic fluid (placental and liver-bone-kid-
' ney alkaline phosphatase) revealed that no fetal intesti-
! nal alkaline phosphatase was present in the supernatant.
Absolutely no activity could be detected in the region
corresponding to fetal intestinal alkaline phosphatase
(results not shown).
Assays of inhibition of the enzyme present in the pellet
showed a behaviour similar to that of fetal (and adult)
intestinal isozyme. In the presence of 2.5 mmol/1 Z,-phe-
nylalanine, the enzyme showed a 60% inhibition; that
extracted from meconium 65% and that from adult intes-
tine 62%. With 10 mmol/1 Ζ,-homoarginine, inhibition
was 25% for the enzyme in the pellet, 20% for that from
meconium and 21% for that in adult intestinal mucosa.
Inhibition of the alkaline phosphatase contained in the
supernatant after centrifiigation at 100 000 g was 52%
with L-phenylalanine and 48% with I-homoarginine.
Reported values of inhibition of the placental isozyme
are 70% with 2.6 mmol/1 £-phenylalanine and 9% with
10 mmol/1 L-homoarginine and for liver-bone-kidney-
isozyme, 9.5% and 80% for Ζ,-phenylalanine and Ζ,-ho-
moarginine respectively (15).
Determination of alkaline phosphatase
isozyme activity in amniotic fluid
The total alkaline phosphatase activity in amniotic fluid
free of cells and debris (supernatant after 10 000 g cen-
trifugation) gave a rnean value of 25.0 (s. d. 6.6) U/l in
30 samples. This value corresponds to 100% activity.
Since practically all the fetal intestinal alkaline phospha-
tase is separated in the 100 000 g pellet, the alkaline
phosphatase activity of the supernatant after 100 000 g
centrifugation subtracted from total activity gives the
amount of intestinal alkaline phosphatase. The mean
value for this fraction was 20.3 (s. d. 6.6) U/l, which
corresponds to 81% of the total activity. It is known that
the placental isozyme is more stable to heat than the
other isozymes (16). Activity in the supernatant after
heating at 56 °C for 90 min corresponds only to the
placental alkaline phosphatase because the other iso-
zymes are inactivated by such treatment. Its mean
value was 1.85 (s.d. 1.35) U/l or 7.5% of the total.
Liver-bone-kidney alkaline phosphatase activity is the
difference between enzymic activity in supernatant mi-
nus remaining activity after heating (placental iso-
zyme). Thus, the difference of alkaline phosphatase in
the supernatant and placental isozyme corresponds to
the liver-bone-kidney isozyme. The average value was
2.9 (s.d. 1.7) U/l or 12% of the total.
Discussion
The method presented allows determination of the three
isozymes of alkaline phosphatase (fetal intestinal, pla-
cental and liver-bone-kidney) present in amniotic fluid.
The proportion of each of the molecular forms obtained
with this technique in amniotic fluid during the second
trimester of pregnancy is similar to that found by other
authors using immunochemical methods or combined
inhibitors (9, 10).
The fetal intestinal alkaline phosphatase is the most
abundant isozyme in amniotic fluid from the 15th to the
20th week of gestation. This form is associated with the
microvilli which are continuously being sloughed and
incorporated into the meconium and finally suspended
in the amniotic fluid. This isozyme in the amniotic fluid
is bound to membranous structures forming an aggre-
gate or complex with a molecular mass greater than one
million (14). As demonstrated by our results, this com-
plex can be precipitated by centrifugation at 100 000 g
for 90 min. Previously, we had communicated the sepa-
ration of high Mr (biliary alkaline phosphatase), another
membrane-associated alkaline phosphatase from serum
of cholestatic patients, using a similar procedure (17).
The fraction obtained in the 100 000 g pellet of amni-
otic fluid showed the electrophoretic characteristics
and inhibition by L-phenylalanine and L-homoarginine
typical of fetal intestinal alkaline phosphatase. Abso-
lutely no fetal intestinal alkaline phosphatase activity
could be detected in the supernatant of 100 000 g.
Conversely, only the fetal intestinal isozyme was
found in the pellet, which did not show contamination
with other isozymes.
Although the advances of molecular biology offer tech-
niques with a high degree of accuracy, alkaline phospha-
tase determination in amniotic fluid is still a convenient
method for most clinical laboratories.
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The procedure presented here further simplifies the tech-
nique, since it does not requirerthe use of control iso-
zymes, monoclonal antibodies or use of combined inhib-
itors to determine the fetal intestinal alkaline phospha-
tase. Further investigation is required to assess the pos-
sible usefulness of this method for the prenatal diagnosis
of cystic fibrosis.
Acknowledgements
We thank Dr. Antonio Blanco for advice and critical revision of the
manuscript. This work was partially supported by a grant from
the Consejo de Investigaciones Cientificas y Tecnologicas de la
Provincia de Cordoba (CONICOR) and the Secretaria de Cieneia
y Tecnologia de la Universidad Nacional de Cordoba (SECyT).
References
1. Mullivor RA, Mennuti MT, Harris H. Origin of alkaline phos-
phatase in amniotic fluid. J Obstet Gynecol 1979; 135:77-81.
2. Muller F, Berg S, Frot JC, Bouer J, Bouer A. Prenatal diagnosis
of cystic fibrosis I: prospective study of 51 pregnancy. Prenat
Diagn 1985; 5:97-108.
3. Papp Z, Toth A, Szabo M, Teichmann F, Szeifert GT, Toth M,
Totok 0. Early prenatal diagnosis of cystic fibrosis by ultra-
sound. Clin Genet 1985; 28:356-8.
4. Gilbert F. Genetic diagnosis and population screening of cystic
fibrosis. Nature 1985; 318:382-4.
5. Brock DJH. Amniotic fluid alkaline phosphatase isoenzymes
in early prenatal diagnosis of cystic fibrosis. Lancet 1984;
1:102.
6. Tsui LC, Buchwald M, Barker D, Bramn JC, Knowlton R,
Schumm JW, et al. Cystic fibrosis locus defined by a geneti-
cally linked polymorphic DNA marker. Science 1985;
230:1054-7.
7. Wainwright BJ, Scambler PJ, Schmidtke J, Watson EA, Law
H, Farrall M, et al. Localization of cystic fibrosis locus to hu-
man chromosome 7q22. Nature 1985; 318:384.
8. White R, Woodward S, Leppert M, O'Connell P, Hoff M,
Herbst J, et al. A closely linked genetic marker for cystic fibro-
sis. Nature 1985; 318:382-4.
9. Mullivor RA, Hanning VL, Harris H. Quantitative analysis of
alkaline phosphatase in serum and amniotic fluid: comparison
of biochemical and immunologic assays. J Lab Clin Med
1985; 105:342-8.
10. Brock DJH, Barron L, Bedgoof D, van Heyningen V. Prenatal
diagnosis of cystic fibrosis using a monoclonal antibody spe-
cific for intestinal alkaline phosphatase. Prenat Diagn 1984·
4:421-6.
11. Morton RK. The purification of alkaline phosphatase of animal
tissues. Biochem J 1954; 57:595-603.
12. Walter K, Schutt Ch. Methods of enzymatic analysis, 2nd edn.
Bergmeyer HU, editor. New York: Academic Press,
1974:856-60.
13. Ogita Z, Markert CL. A miniaturized system for electrophore-
sis on polyacrylamide gels. Anal Biochem 1979; 99:233-41.
14. Moss DW, Whitaker KB. The physical characteristics and en-
zymatic modifications of fetal intestinal alkaline phosphatase
in amniotic fluid. Ctin Biochem 1987; 20:9-12.
15. Vergner HA, Brisson Longarre A, Grozdea JG, Blum CJ, Kihn
Y, Sevely J. Nuclear localization and characterization of alka-
line phosphatase in neutrophils from normal controls and preg-
nant women. Ann J Hematol 1992; 39:249-56.
16. Vengerov Y, Gudima AV, Vorpnov AV, Votrin I. Immiino-
chemical studies of human placental alkaline phosphatase in
normal and neoplastic tissues. In: Weber G, editor. Advances
in enzyme regulation, New York: Pergamon Press,
1988:345-54.
17. Moreno J, Vera MC, Yorio M. Methods for determining high-
Mr (biliary) alkaline phosphatase in plasma. Clin Chem 1992;
36:319-20.
Dr. Jose Moreno Barral
Catedra de Quimica Biologica
Facultad de Ciencias Medicas
Universidad Nacional de Cordoba
Casilla de Correo 35, Sue. 16
5016 Cordoba
Argentina
Eur J Clin Chem Clin Biochem 1995; 33 (No 5)
